

PTO/SB/30 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Request For Continued Examination (RCE) Transmittal

Address to:
Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Application Number	10761,636
Filing Date	January 21, 2004
First Named Inventor	Bernard Frank Bishop
Art Unit	1623
Examiner Name	Traviss C. McInerney
Attorney Docket Number	PC22004B

FAX RECEIVED

SEP 15 2006

OFFICE OF PETITIONS

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application. Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.

1. **Submission required under 37 CFR 1.114** Note: If the RCE is proper, any previously filed unentered amendments and amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such amendment(s).

- a. ☐ Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked.

- i. ☐ Consider the arguments in the Appeal Brief or Rely Brief previously filed on _____

- ii. ☐ Other _____

- b. ☒ Enclosed

- i. ☐ Amendment/Reply

- iii. ☒ Information Disclosure Statement (IDS)

- ii. ☐ Affidavit(s)/Declaration(s)

- iv. ☐ Other _____

2. Miscellaneous

- a. ☐ Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of _____ months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(l) required)
- b. ☐ Other _____

3. Fees

The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed. The Director is hereby authorized to charge the following fees, or credit any overpayments, to

- a. ☒ Deposit Account No. 21-0718 The total amount charged is \$ 790.00

- i. ☒ RCE fee required under 37 CFR 1.17(e)

- ii. ☐ Extension of time fee (37 CFR 1.136 and 1.17). A _____ month extension is requested.

- iii. ☐ Other _____

- b. ☐ Check in the amount of \$ _____ enclosed

- c. ☐ Payment by credit card (Form PTO-2038 enclosed)

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

Name (Print/Type)	Thomas A. Wootton	Registration No. (Attorney/Agent)	35,004
Signature	<i>Thomas A. Wootton</i>	Date	September 15, 2006

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop RCE, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 or facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below.

Name (Print/Type)	Jennifer S. Naylor	Date	September 15, 2006
Signature	<i>Jennifer S. Naylor</i>		

This collection of information is required by 37 CFR 1.114. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

09/18/2006 CKHLOK 00000023 210718 10761636

02 FC:1801 790.00 DA

PATENT/Docket No. PC22004B
Appl. No. 10/761,636
Filing Date: January 21, 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

FAX RECEIVED

SEP 15 2006

OFFICE OF PETITIONS

Art Unit : 1623
Examiner : Traviss C. McIntosh III
Applicant(s) : Bernard Frank Bishop
Serial Number : 10/761,636
Filed : January 21, 2004
For : AVERMECTIN AND PRAZIQUANTEL COMBINATION THERAPY

Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450


REQUEST FOR CONTINUED EXAMINATION

Sir:

Applicant hereby files a Request for Continued Examination of the above-referenced patent application in compliance with § 1.114. Subsequent to the payment of the issue fee on August 7, 2006, Applicant received a communication from a foreign examining authority citing additional prior art resulting from the foreign examination. Therefore, the present Request for Continued Examination is being filed in order to have the newly discovered art examined.

Attached is a Request for Continued Examination (RCE) Transmittal authorizing the payment of the \$790.00 fee. Please charge any additional fees or credit any overpayments to Deposit Account Number 21-0718.

Respectfully submitted,


Thomas A. Wootton, Attorney
Registration No. 35,004

Date: 15 September 2006

Pharmacia & Upjohn Company
7000 Portage Road
Kalamazoo, Michigan 49001
Telephone No. (269) 833-7914 or (269) 833-9500
Telefax No. (269) 833-8897 or (269) 833-2316

FORM AMEND
Rev. 5/27/03